Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Uday Popat

Uday Popat

MD
The University of Texas MD Anderson Cancer Center
A Phase II trial of busulfan, fludarabine, cladribine, thiotepa, and venetoclax conditioning for AML 3:16
A Phase II trial of busulfan, fludarabine, cladribine, thiotepa, and venetoclax conditioning for AML
Uday Popat • 8 Dec 2025
Further optimizing conditioning regimens for patients with MPNs to improve transplant outcomes 1:22
Further optimizing conditioning regimens for patients with MPNs to improve transplant outcomes
Uday Popat • 23 Aug 2025
The evolving role of stem cell transplantation in MPNs 0:43
The evolving role of stem cell transplantation in MPNs
Uday Popat • 23 Aug 2025
Conditioning regimen optimization in stem cell transplantation for MPNs 3:51
Conditioning regimen optimization in stem cell transplantation for MPNs
Uday Popat • 23 Aug 2025
Key factors that influence conditioning intensity and moving toward personalized conditioning in AML 3:56
Key factors that influence conditioning intensity and moving toward personalized conditioning in AML
Uday Popat • 28 May 2025
A myeloablative fractionated busulfan conditioning regimen with sorafenib for alloSCT in AML 7:35
A myeloablative fractionated busulfan conditioning regimen with sorafenib for alloSCT in AML
Uday Popat • 28 May 2025
Challenges associated with transplantation in patients with MPNs 1:34
Challenges associated with transplantation in patients with MPNs
Uday Popat • 25 Aug 2024
Stem cell transplant in MPNs: session highlights and key takeaways 2:05
Stem cell transplant in MPNs: session highlights and key takeaways
Uday Popat • 25 Aug 2024
Optimizing conditioning regimens for stem cell transplantation in myelofibrosis 4:04
Optimizing conditioning regimens for stem cell transplantation in myelofibrosis
Uday Popat • 25 Aug 2024
Selecting patients with MPNs for stem cell transplantation 0:46
Selecting patients with MPNs for stem cell transplantation
Uday Popat • 25 Aug 2024
Optimizing myeloablative conditioning regimens in older patients receiving alloHSCT 3:01
Optimizing myeloablative conditioning regimens in older patients receiving alloHSCT
Uday Popat • 23 Apr 2022
Sorafenib or venetoclax in fractionated busulfan conditioning regimen for AML & MDS 2:31
Sorafenib or venetoclax in fractionated busulfan conditioning regimen for AML & MDS
Uday Popat • 23 Apr 2022
Myeloablative conditioning regimen with PTCy in elderly patients with AML and MDS 3:23
Myeloablative conditioning regimen with PTCy in elderly patients with AML and MDS
Uday Popat • 23 Apr 2022
The content of VJHemOnc is intended for healthcare professionals